Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ortho licenses Agen's D-dimer heart attack test

This article was originally published in Clinica

Executive Summary

Australian company Agen has licensed its D-dimer blood clot tests to Ortho Diagnostic Systems on a non-exclusive basis. The test is based on the DD3B6/22 monoclonal antibody which, like the Washington soluble fibrinogen test, recognises the signs of clot degradation. Announcing the deal just one day after the ACC meeting, Agen's managing director, Roman Zwolenski, said: "The worldwide D-dimer testing market is estimated to be worth US$45 million, and growing significantly." This is Agen's second licence agreement since the European Patent Office upheld its D-dimer patent. Agen is collaborating on the development of an instrument for rapid heart attack testing with US company Source Scientific.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT084062

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel